Nuvation Bio Inc. (NUVB): Results of Operations and Financial Condition
Nuvation Bio Inc. (NUVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI is the most prescribed ROS1 TKI i
How this was made
The 30-second read
Why it matters
Traders can use the cash balance and convertible notes proceeds for runway assessment, while the FDA sNDA acceptance with a defined action date and MHRA MAA validation provide concrete near-to-medium term catalysts. Clinical long-term follow-up updates for both programs can shift sentiment around durability and development expansion.
Market read
Primary filing with quantified revenue and cash, plus specific regulatory timelines (FDA action date) and updated long-term clinical data that can drive biotech risk re-pricing.
What to watch
The excerpt emphasizes milestones but does not quantify updated commercial forecasts, margin trajectory, or any changes to probability of success for the FDA decision beyond the stated action date.
Nuvation Bio reported $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI, while reporting a net loss of $62.8 million and ending the quarter with $661.0 million in cash, cash equivalents, and marketable securities.
IBTROZI product revenue grew 25% quarter-over-quarter and the company reported substantial liquidity, but operating expenses increased year-over-year and net loss widened to $62.8 million from $59.0 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $31.7 million | – | – |
| IBTROZI net product revenueGAAP | $23.2 million | 25% | – |
| Collaboration and license agreements revenueGAAP | $8.5 million | – | – |
| Royalty revenue from collaboration agreements for China and JapanGAAP | $2.1 million | – | – |
| Research and development expensesGAAP | $30.7 million | – | – |
| Selling, general and administrative expensesGAAP | $42.6 million | – | – |
| Net lossGAAP | $62.8 million | – | – |
| Net loss per share, basic and dilutedGAAP | $(0.18) per share | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| IBTROZI U.S. product revenueContinued adoption and durability of treatment. | $23.2 million | 25% | – |
| Collaboration and license agreementsThe increase is primarily due to a $3.6 million increase in product supply, and a $1.8 million increase in royalty revenue, offset by a $0.5 million decrease in research and development service revenue. | $8.5 million | – | – |
What drove it
- IBTROZI was the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026 based on IQVIA claims from the first five months of the year.
- About 85% of the approximately 160 new IBTROZI patient starts were TKI-naïve, representing about 30% quarter-over-quarter growth in that setting.
- Taletrectinib was included in China’s National Reimbursement Drug List effective January 1, 2026.
- The FDA accepted the IBTROZI supplemental New Drug Application, with a target action date of January 4, 2027.
- Nuvation Bio initiated the G307 pivotal Phase 3 study and the G209 Phase 2 study for safusidenib in July 2026.
Concerns
- Net loss was $62.8 million, compared to $59.0 million for the three months ended June 30, 2025.
- Research and development expenses were $30.7 million, compared to $27.4 million for the three months ended June 30, 2025, primarily reflecting a $4.6 million increase in third-party clinical trial costs.
- Selling, general and administrative expenses were $42.6 million, compared to $38.5 million for the three months ended June 30, 2025.
- To date, the company’s only source of product revenue remains U.S. sales of IBTROZI.
- No financial guidance was provided.
What to watch
- FDA action on the IBTROZI supplemental New Drug Application by January 4, 2027.
- Further updates on new drug-drug conjugate platform preclinical candidates by year-end 2026.
- Progression of the G307 pivotal Phase 3 study in grade 2 IDH1-mutant glioma outside the U.S. and the G209 Phase 2 study in patients whose IDH1-mutant glioma progressed after prior vorasidenib treatment in the U.S.
- UK MHRA review of the Marketing Authorisation Application submitted by Eisai Co., Ltd. for taletrectinib.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $661.0 million as of June 30, 2026.
- The July 2026 public offering of 0.75% Convertible Senior Notes generated estimated net proceeds of approximately $279.1 million, net of fees and related reimbursements.
- Net proceeds of $36.5 million from exercise of the overallotment option occurred in July 2026 and were not reflected in the June 30, 2026 cash balance.
- The company concurrently entered into capped call transactions at a cap price of $10.4580 per share, representing an 80.0% premium over the last reported sale price of $5.81 per share.
Analysis
Nuvation Bio reported $31.7 million in total revenue for the second quarter of 2026, led by $23.2 million of IBTROZI net product revenue. IBTROZI product revenue grew 25% quarter-over-quarter. The company said about 85% of approximately 160 new patient starts were TKI-naïve, with about 30% quarter-over-quarter growth in that setting, supporting the reported shift toward earlier-line use. Collaboration and license agreements revenue was $8.5 million, compared with $3.6 million in the prior-year period, with product supply and royalty revenue identified as the principal drivers.
Expenses increased as the company expanded clinical activity and commercial infrastructure. Research and development expenses were $30.7 million versus $27.4 million, primarily due to a $4.6 million increase in third-party clinical trial expense, partly offset by a $1.3 million decline in personnel costs. Selling, general and administrative expenses were $42.6 million versus $38.5 million, with higher headcount and stock-based compensation, legal fees, professional fees, sales and marketing expense, foreign currency impact, and miscellaneous expense all cited. Net loss was $62.8 million, or $(0.18) per share on a basic and diluted basis, compared with $59.0 million, or $(0.17) per share.
The clinical and regulatory update broadened the pipeline agenda beyond IBTROZI commercialization. The FDA accepted the IBTROZI supplemental New Drug Application with a target action date of January 4, 2027. For safusidenib, the company reported a centrally assessed ORR of 51.9%, a 36-month PFS rate of 79.1%, and median PFS not reached at a median of 38.8 months of follow-up in the Phase 2 J201 study. Nuvation Bio initiated G307 and G209 to extend safusidenib development across additional IDH1-mutant glioma settings.
Liquidity was $661.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026. That balance excludes $36.5 million in net proceeds from the convertible senior notes overallotment option exercised in July 2026. The company also completed a July 2026 offering of 0.75% Convertible Senior Notes with estimated net proceeds of approximately $279.1 million and entered capped call transactions. The release did not provide forward financial guidance, leaving subsequent IBTROZI revenue progression, operating spending, and the timing of clinical updates as the principal reported items to monitor.
Management, verbatim
IBTROZI is now the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026, based on IQVIA claims data from the first five months of the year, reflecting the medical community’s growing conviction that IBTROZI’s durability profile belongs at the front of the treatment sequence.
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio
We are equally excited about the progress of safusidenib, with our updated Phase 2 data showing further deepening and durable responses in IDH1 -mutant gliomas.
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio
Not in the filing
stated, not guessed- Gross profit
- Gross margin
- Operating income or operating loss
- Total revenue prior-year comparison
- Total revenue prior-quarter comparison
- IBTROZI net product revenue prior-year comparison
- IBTROZI net product revenue prior-quarter amount
- Collaboration and license agreements revenue percentage change
- Non-GAAP revenue, earnings, EPS, or expense measures
- Operating cash flow
- Free cash flow
- Debt balance as of June 30, 2026
- Share repurchases
- Dividends
- Forward financial guidance
- Prior outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8-K Item 2.02 with Exhibit 99.1 covering Q2 2026 financial results and business updates for Nuvation Bio’s lead programs: IBTROZI (taletrectinib) and safusidenib.
Ticker impact
Nuvation Bio reports Q2 2026 results and updates, including $23.2M net product revenue for IBTROZI and a Jan 4, 2027 FDA sNDA action date.
Likely positive bias for near-term trading as investors price in FDA timeline (Jan 4, 2027) and continued ROS1 adoption plus long-term Phase 2 updates.
This is a primary SEC 8-K with concrete revenue, cash balance, and specific regulatory/clinical milestones; however, the excerpt does not include the full guidance or any explicit approval decision, limiting certainty on magnitude.
Market effects
Reinforces investor appetite for oncology small/mid-cap stories with durable efficacy claims and advancing regulatory timelines.
UK MHRA validation and US FDA acceptance can support cross-market sentiment for biotech with global development partners.
Highlights ongoing global regulatory engagement (FDA, MHRA) and long-term follow-up data that can influence broader ROS1 and IDH1-mutant glioma read-through.
Counterpoint
Durability and adoption claims may already be partially anticipated; without an approval decision, the market may fade the news if expectations were high.
Key entities
- issuerNuvation Bio Inc.
Company filing the 8-K and reporting Q2 2026 financial results plus regulatory and clinical program updates.
- productIBTROZI (taletrectinib)
ROS1 inhibitor referenced with Q2 net product revenue and regulatory milestones (FDA sNDA acceptance; MHRA MAA validation).
- investigational drugsafusidenib
IDH1-mutant glioma program with updated long-term Phase 2 follow-up and expansion into new studies.
- partnerEisai Co., Ltd.
Named partner for the UK MHRA validated marketing authorization application for taletrectinib.
- partnerThermo Fisher Scientific
Named for process technology transfer and product introduction for U.S.-based manufacturing of IBTROZI.
